|1.||Fisher, Aron B: 4 articles (01/2012 - 10/2003)|
|2.||Chatterjee, Shampa: 4 articles (01/2012 - 10/2003)|
|3.||Ghasemi, Mehdi: 3 articles (01/2010 - 06/2007)|
|4.||Dehpour, Ahmad Reza: 3 articles (01/2010 - 06/2007)|
|5.||Buck, Leslie Thomas: 2 articles (10/2010 - 02/2008)|
|6.||Shafaroodi, Hamed: 2 articles (01/2010 - 06/2007)|
|7.||Ebrahimi, Farzad: 2 articles (01/2010 - 06/2007)|
|8.||Sadeghipour, Hamed: 2 articles (09/2007 - 06/2007)|
|9.||Asadi, Shahrzad: 2 articles (09/2007 - 06/2007)|
|10.||Lee, Jeong Hyun: 2 articles (01/2003 - 05/2002)|
|1.||Asthma (Bronchial Asthma)
02/01/1993 - "After a single oral dose of BRL 38227 no beneficial effect on airway function was detected, despite a high incidence of side effects, which indicates that the orally administered K+ channel activator BRL 38227 may not be useful in the management of asthma."
01/01/1992 - "7. The active enantiomer of cromakalim has been found to be effective in alleviating nocturnal asthma at plasma concentrations just threshold for relaxing human airways smooth muscle in vitro. "
02/01/1993 - "In the third study the effect of 0.5 mg of BRL 38227 or placebo was assessed in eight patients with mild asthma. "
01/01/1992 - "2. While clinical trials have indicated that cromakalim may be of benefit in the treatment of nocturnal asthma, it remains to be determined whether KCOs will find a place in our armamentarium of clinically useful anti-asthma agents. "
01/01/1992 - "The mechanism of action of cromakalim in alleviating nocturnal asthma may not involve direct relaxation of airways smooth muscle. "
10/01/1989 - "Intracellular electrophysiological studies showed that ischemia-induced depolarization was reversed with cromakalim, which increased the resting potential nearly back to preischemic levels.(ABSTRACT TRUNCATED AT 250 WORDS)"
05/15/2012 - "Eight-week-old male Sprague-Dawley rats were divided into three groups: control and IR rats without or with cromakalim (300 μg/kg intraperitoneally), 30 min before the induction of ischemia. "
06/01/1997 - "cromakalim) are thought to be cardioprotective during ischemia-reperfusion, while KATP blockers (e.g. "
12/01/1996 - "Prevention of Na+ and Ca2+ accumulation after ischemia might be a reason for cardioprotective effect of cromakalim on neonatal New Zealand white rabbit heart."
12/01/1996 - "Measurements of cation contents with atomic absorption method revealed that intracellular K+ content was lower in cromakalim pretreated group at preischemia, end of ischemia and 20 min after ischemia. "
06/01/1997 - "Hearts were subjected to 25 min total global ischemia at 36.5 degrees C and reperfused for 45 min. Pre-treatment with cromakalim delayed the time to ischemic contracture (19.3 +/- 1.5 min v 15.3 +/- 0.6 for control, P < 0.05) and significantly improved recovery of function at 45 min reperfusion (84 +/- 11% pre-ischemic rate pressure product (RPP) v 38 +/- 5 for control, P < 0.05). "
02/16/1993 - "After 30 min of reperfusion, pretreatment with KRN2391 and cromakalim resulted in a significant improvement in cardiac function, ischemic contracture and biochemical parameters. "
08/01/1993 - "In animal PVD models, SDZ PCO-400 and cromakalim have been shown to improve recovery of muscle energy stores from ischemia or to preserve performance under conditions of ischemic contracture. "
06/01/2001 - "In isolated rat hearts subjected to 25 min of global ischemia and 30 min of reperfusion, BMS-191095 increased the time to onset of ischemic contracture with an EC(25) of 1.5 microM, which is comparable to 4.7 microM and 3.0 microM for cromakalim and BMS-180448, respectively. "
|4.||Hypertension (High Blood Pressure)
08/01/1995 - "In this study, we treated 14 patients with essential hypertension on an out-patient basis to investigate the antihypertensive effect of levcromakalim by 24-h blood pressure monitoring for a 12-weeks treatment period. "
03/01/2001 - "Salt-induced hypertension in rats alters the response of isolated aortic rings to cromakalim."
08/01/1995 - "Antihypertensive effect of levcromakalim in patients with essential hypertension. "
06/01/1994 - "Cromakalim (BRL 34915), a novel vasodilator, is used clinically to manage systemic hypertension. "
09/01/1991 - "Effect of short-term administration of cromakalim on renal hemodynamics and eicosanoid excretion in essential hypertension."
05/01/2009 - "The authors tested the efficacy of locally delivered intrathecal cromakalim, a PCO, incorporated into a controlled-release system to prevent cerebral vasospasm in a rat model of SAH. "
05/01/1999 - "The present study examined the effect of a K+ channel activator, cromakalim, on cerebral vasospasm following experimental SAH. "
02/01/1998 - "The present study examined the effects of systemic administration of a K+ channel activator, cromakalim, on cerebral vasospasm after experimental SAH. "
05/01/2009 - "The authors' results confirm that sustained delivery of cromakalim perivascularly to cerebral vessels could be an effective therapeutic strategy in the treatment of cerebral vasospasm after SAH."
01/01/2000 - "These findings indicate that cromakalim dose-dependently attenuates cerebral vasospasm when administered 24 hours after experimental SAH in the rabbit. "
|2.||Potassium Channels (Potassium Channel)
|4.||Histamine (Histamine Dihydrochloride)
|5.||Aspirin (Acetylsalicylic Acid)
|8.||SDZ PCO 400
|9.||N- cyano- N'- (2- nitroxyethyl)- 3- pyridinecarboximidamide methanesulfonate